FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder - Investing News Network

Submitted by Anonymous (not verified) on Thu, 11/06/2025 - 13:39

FDA approval of CAPLYTA® has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder  Investing News Network